Objective. We aimed to test the relevance of deficiency of adenosine deaminase 2 (DADA2) in patients with antibody deficiency and describe the clinical picture of the disease in adulthood.
the degradation of adenosine to inosine and is secreted by myeloid cells (3) . The pathomechanism of DADA2 remains unclear, but ADA2 seems to have an immunomodulatory function (4) . While DADA2 is primarily considered a vascular disease of childhood, recent evidence suggests that the clinical spectrum is not limited to vasculitis, arthralgias, and recurrent fevers, but can also include features of autoimmunity and immunodeficiency. Indeed, using whole-exome sequencing, we recently identified compound heterozygous CECR1 mutations in 2 siblings with immunodeficiency and immune dysregulation, suggesting that DADA2 may also present with isolated antibody deficiency (5) .
Although most of the patients described originally were children, our index patient was 32 years old and was diagnosed as having common variable immunodeficiency at age 24 following a progressive decline in his immunoglobulin levels and increasing susceptibility to infections. Consequently, we screened a cohort of 181 adolescent and adult patients with antibody deficiency or common variable immunodeficiency for mutations in CECR1. The aims of this study were to explore the immunologic features of DADA2, determine the clinical picture of the disease in adulthood, and evaluate the therapeutic management of the disease from the perspective of adult medicine.
PATIENTS AND METHODS
Patients and controls. All procedures involving human participants were performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was conducted under approved ethics protocol no. 322/15 dated July 28, 2015 from the University of Freiburg Medical Center. Written consent was obtained from all patients or their parents and all healthy controls. Inclusion criteria included antibody deficiency with or without vascular manifestations, availability of DNA for study purposes, and a signed consent for genetic studies. Data recorded at the time of diagnosis were sex, age, ethnicity, clinical manifestations, hematologic values, lymphocyte subsets, immunoglobulin levels, and treatment. Data were collected in a standardized format.
Genetic evaluation. Patients (n 5 181) were screened for mutations in CECR1. Of these, 177 were screened using a next-generation sequencing (NGS)-based approach on a common variable immunodeficiency panel containing 120 candidate genes, including CECR1. All CECR1 mutations identified by NGS were confirmed by Sanger sequencing. Four additional patients were identified after being selected for targeted Sanger sequencing due to a clinical phenotype of immunodeficiency and vasculopathy that was suspicious for DADA2, or because they were siblings of DADA2 patients who were identified by NGS. All mutations were confirmed on a functional level by ADA2 activity measurement.
Next-generation sequencing. Sequencing data were generated by targeted panel resequencing. A HaloPlex Target Enrichment System for Illumina Sequencing (Agilent) was used for target enrichment. A customized gene panel containing 120 candidate genes was designed using Agilent's webbased SureDesign application. The manufacturer's instructions as detailed in Agilent's user manual were subsequently followed for digesting the DNA samples, hybridizing the restriction fragments, capturing the target DNA, closing the circular fragments through a ligation reaction, and purifying the amplified target libraries. Enrichment was validated on a 2100 Bioanalyzer system (Agilent). Samples were then pooled in equimolar amounts for multiplexed sequencing on a MiSeq system (Illumina). They were prepared for sequencing using an Illumina version 2 reagent kit, as indicated in the protocol. After denaturation with NaOH, the libraries were diluted to a final concentration of 8-12 pM. The MiSeq system was loaded and started according to the instructions provided in the user guide. Data analysis was performed with the help of Agilent's SureCall software.
Sanger sequencing. Coding genomic regions including flanking intronic sequences of CECR1 were amplified from genomic DNA, or exonic regions from copy DNA, by standard polymerase chain reaction (PCR). PCR primers were used for Sanger sequencing according to standard techniques. Primer sequences are available upon request from the corresponding author.
ADA2 activity measurement. ADA2 activity was measured using the high-performance liquid chromatography method described by Zhou et al (1) , modified to perform the measurement on extracts of dried plasma spots on filter paper instead of EDTA-treated plasma, as described elsewhere (6) . During development of the dried plasma spot method, ADA2 activity was initially normalized to both total protein and albumin in the spot extracts. However, after the 2 approaches were found to be comparable, we decided to express the results of the present study as mU of ADA2 activity per mg of total extract protein (Kelly SJ, Ganson NJ, Hershfield MS: unpublished observations).
Western blot analysis. Peripheral blood mononuclear cells (PBMCs) were isolated from freshly drawn EDTA-treated blood via Ficoll isolation. Healthy donor controls were matched for sex and age with the patients. Monocytes were isolated from the PBMCs with CD14 Microbeads (catalog no. 130-050-201; Miltenyi). Purity was controlled by flow cytometry and was always .93%. Cells were stained with allophycocyanin-conjugated CD14 (catalog no. 325608; BioLegend) and DAPI (catalog no. D9542; Sigma) to exclude dead cells. They were analyzed with a BD FACSCanto II. The monocytes were lysed using cell lysis buffer (catalog no. 9803; Cell Signaling Technology). Protein concentration was determined using a Pierce BCA Protein Assay Kit (catalog no. 23225; Thermo Fisher Scientific). For each sample, 20 mg of total protein was analyzed by Western blotting using 10% polyacrylamide gel (Mini-PROTEAN Electrophoresis System; Bio-Rad). The primary antibody for ADA2 (1:300) (catalog no. HPA007888; Sigma) was incubated overnight at 48C. The corresponding secondary antibody (horseradish peroxidaseconjugated donkey anti-rabbit IgG; 1:5,000) (catalog no. sc-2077; Santa Cruz Biotechnology) was then incubated for 1 hour at room temperature. Anti-b-actin (catalog no. NB600-501; Novus Biologicals) was used as a loading control, following the same protocol.
RESULTS
Results of genetic screening. We screened 177 patients using NGS and identified 5 patients with mutations in CECR1. Four additional patients were identified after they were selected for targeted Sanger sequencing due to a phenotype of immunodeficiency and vasculopathy that was clinically suspicious for DADA2, or because they were siblings of patients with DADA2 who had been identified by NGS. Including the 2 siblings of the index family (5), we identified 4 previously published and 6 novel CECR1 mutations, with 4 splice site mutations among them. The mutations were distributed across the whole CECR1 gene and were either homozygous or compound heterozygous ( Figure  1A ). All mutations were confirmed on a functional level by demonstrating very low or absent ADA2 enzymatic activity in dried plasma spots from all 10 living patients ( Figure 1B ). ADA2 expression was tested by Western blotting on monocyte lysates in 4 available patient samples. Protein expression was absent in all patients, in contrast to the healthy donor controls ( Figure 1C) .
Three patients had compound heterozygous or homozygous splice site mutations. In patient 2 (C408Y/ c.54211G.A), the retention of intron 3 would lead to the insertion of 11,753 additional basepairs, thus rendering the degradation of the product of the affected allele The mutations were spread across the whole gene. B, ADA2 enzymatic activity measured in dried plasma spots from DADA2 patients and controls. Activity was low in all 10 living patients compared to the range in 16 healthy individuals. C, Western blot analysis of ADA2 in patients and healthy donors (HDs). The CECR1 mutations led to undetectable protein expression on the monocyte lysates of 4 DADA2 patients. Healthy donor controls were matched for sex and age with the patients. Actin was used as a loading control.
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at the RNA level very likely ( Figure 2A ). Indeed, when the patient's complementary DNA (cDNA) was sequenced, only the wild-type sequence was detected (Figure 2B ). The absence of protein expression is shown in Figure 1C . In patient 5, the homozygous splice site mutation c.973-1G.A was predicted to lead to the deletion of exon 6 ( Figure 2C ). Indeed, sequencing the cDNA showed a direct transition from exon 5 to exon 7 ( Figure  2D ). A cDNA sample was not available for patient 11 (c.97213A.G/c.973-2A.G). However, both mutations were predicted to lead to similar consequences as described above. The mutation c.97213A.G would cause the retention of intron 6, which would lead to the insertion of 1,056 additional basepairs. The second mutation, c.973-2A.G, would lead to the deletion of exon 6. On a functional level, the splice site mutations did not differ from the point mutations, all resulting in very low enzymatic activity of ADA2.
Clinical characterization of the cohort. Clinically, we saw a broad range of phenotypes, from isolated antibody deficiency to recurrent strokes. Figure 3 gives an overview of the distribution of clinical features in the cohort, and Table 1 shows the individual patients' features. Of 11 DADA2 patients, 4 were female and 7 were male. The patients' ages at evaluation ranged from 13 to 51 years, with a median of 22 years. The age at onset ranged from 2 to 33 years, with a median of 8 years. The symptoms at onset were variable, including erythema nodosum, pneumonia, arthralgias, recurring infections (mainly respiratory), PAN, myositis, enteropathy, sinusitis, aphthous stomatitis, and meningitis. The leading diagnosis before identification of the molecular cause of the disease varied. Five patients (patients 2, 3, 5, 10, and 11) had been diagnosed as having common variable immunodeficiency, and 1 patient (patient 9) had been diagnosed as having antibody deficiency. Two patients (patients 1 and 6) were treated for recurrent strokes or vasculitis and antibody deficiency. Two brothers (patients 7 and 8) presented with noninfectious episodes of fever and myositis, and the leading diagnosis in another patient (patient 4) was PAN. One patient (patient 6) died at age 17 years due to multiple organ failure following pneumonia which grew Candida and Pseudomonas, and a cerebral bleed that led to incarceration of the tentorial notch (5) .
Vascular manifestations were present in 7 of 11 patients. These included livedo reticularis in 5 patients, strokes, arterial hypertension, and PAN in 3 patients each, and single cases of erythema nodosum and skin ulcers. One female patient had a heart attack at age 51. All patients had immunodeficiency. All patients displayed dys-/hypogammaglobulinemia, with IgA levels below the normal range in all patients, and low IgG and IgM levels in 10 of 11 patients. Two patients had a very low normal IgG or IgM level, respectively. This immunodeficiency also manifested with recurrent infections in 9 of 11 patients. The most commonly observed infections were lower respiratory tract infections (including 5 cases of pneumonia and 1 pulmonary abscess), and upper respiratory tract infections in 7 of 11 patients. Herpes infections were also present in half of the cohort, consisting mainly of recurrent herpes simplex outbreaks and one herpes zoster infection. Intestinal infections and urinary tract infections were seen in 3 patients each, and single cases manifested with meningitis, viral encephalitis, and episcleritis. In several patients, pathogens were identified, including Streptococcus, Haemophilus parainfluenzae, Candida, and Escherichia coli.
Immune dysregulation was also present in the entire cohort. Seven patients had noninfectious episodes of fever. Leukopenia was seen in 2 patients (patients 6 and 10), lymphopenia in 5 patients (patients 2, 3, 5, 6, and 9), anemia in 4 patients (patients 1, 5, 6, and 9), thrombocytopenia in 3 patients (patients 1, 2, and 10), and neutropenia in 1 patient (patient 10). Half of the patients had enteropathy, and 2 patients (patients 3 and 4) had microscopic colitis. Half of the cohort had arthralgias, 2 patients had asthma, and 1 patient had alopecia. Two patients had verrucosis and 1 had eczema.
Organ involvement was also present in the entire cohort. Nine of 11 patients had splenomegaly, 3 patients had hepatomegaly, and 2 had lymphadenopathy. Hepatitis was seen in 4 patients and nephritis in 2, leading to renal insufficiency in 1 patient. Lung abnormalities were also present in 4 patients. Half of the patients also presented with neuromuscular features. These were not only residuals from previous strokes, but also included 3 patients with severe myositis, fibromyalgia, and muscle atrophy. Two patients had neuropsychological symptoms: one had an autism spectrum disorder and the other one had intellectual disability and epilepsy following severe meningitis at age 14. Another patient had delayed sexual development. One patient developed a benign pituitary adenoma at age 22. Malignancy was not present in this cohort. Immunologic evaluation. Extended immunologic investigation revealed that 2 patients had leukopenia and 5 had lymphopenia, but T cell subsets were generally normal. The response to antigen stimulation of T cells was normal in 4 of 4 patients (patients 1, 5, 9, and 10; data not shown). Cytotoxicity was addressed in 1 patient (patient 1), and the patient showed no impairment (data not shown).
In contrast to the normal T cell compartment, we observed a compromised B cell compartment as a common feature in DADA2. B cell counts varied, but there was a tendency toward low B cell numbers (in 6 of 11 patients) ( Figure 4A ). Percentages of CD27-IgD1 naive B cells were in the high normal range or elevated in all but 1 patient ( Figure 4B ), whereas CD271IgD-memory B cells were low in all but 1 patient (patient 10) ( Figure  4C ). Consistent with reduced percentages of CD271IgD-memory B cells, all patients had reduced levels of IgA, and all but 1 patient had reduced levels of IgG ( Figure  4D ). However, the levels of IgM were also severely reduced in all but 1 patient ( Figure 4D ), suggesting that the observed B cell defect was not primarily, or at least not only, a result of perturbed class-switch recombination.
Intriguingly, we found that B cell function seemed to worsen with disease progression. There was a significant inverse correlation of C-reactive protein (CRP) levels with IgG levels in 1 patient (patient 3) with long periods of malcompliance with immunoglobulin substitution (r 5 20.90, P 5 0.03707) ( Figure 5A Treatment. Figure 6 gives an overview of the treatments received by our DADA2 patients. Since antibody deficiency was the most common feature in our DADA2 cohort, 9 of 11 patients were receiving ongoing immunoglobulin substitution. Antibiotics were administered to all of the patients, with 3 patients receiving ongoing antibiotic prophylaxis. Two patients were treated with antiviral drugs. One patient had severe oral herpes simplex ulcers and received acyclovir (5 doses of 400 mg each/day for 7 days), leading to an almost complete remission of symptoms, which was sustained by a prophylaxis with 3 doses of 800 mg each/week. The other patient was successfully treated with acyclovir for viral encephalitis at age 13.
Eight patients received immunosuppressive drugs. Steroids were used in 6 patients and steroid-sparing agents in 4 (TNF inhibitors in 3 patients and methotrexate in the patient who died [patient 6]). In addition to the TNF inhibitor, a pyrimidine synthesis inhibitor (leflunomide) was given to 1 patient to control myalgias and paresthesias in the lower extremities. Nevertheless, CRP levels were high (.5 mg/liter) in 7 of the 11 patients, even though at the time of measurement, 1 patient was receiving steroids (patient 5) and 2 were receiving a combination of steroids and steroid-sparing agents (patients 4 Platelet inhibitors were used in 3 patients (acetylsalicylic acid 100 mg/day), and antihypertensive agents in 2. One patient received antiarrhythmic agents. Selective serotonin reuptake inhibitors, tricyclic antidepressants, and antiepileptic drugs were used for pain relief in 1 patient with fibromyalgia (patient 4), allowing relatively stable pain control but no complete remission. Due to severe neutropenia, patient 10 needed granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment. Hematopoietic stem cell transplantation is being considered for this patient.
DISCUSSION
In this study, we evaluated a cohort of 11 adolescent and adult DADA2 patients. All of them had dysgammaglobulinemia/hypogammaglobulinemia and clinical features of immunodeficiency of the B cell compartment. In contrast, vascular manifestations were present in only 64% of the patients (7 of 11). In spite of a selection bias from deliberately screening patients with common variable immunodeficiency and antibody deficiency, we think that a compromised B cell compartment is an intrinsic feature of DADA2, and may reflect a role of ADA2 in the bone marrow microenvironment.
We used CRP levels as a marker of the inflammatory disease activity in DADA2. Therapy was considered successful if CRP levels were ,5 mg/dl. Intriguingly, we saw that CRP levels correlated inversely with immunoglobulin levels in 2 patients with sufficient follow-up data, suggesting that chronic inflammation may lead to an increasingly compromised B cell compartment. Recently, 2 pediatric DADA2 patients with pure red cell aplasia as the only clinical manifestation of their disease were reported to show paucity of erythroid precursors with maturation arrest upon bone marrow evaluation (6) . These findings further strengthen our hypothesis of a possible involvement of ADA2 in the bone marrow microenvironment. Previously published reports show a broad variation of the immunologic phenotype in DADA2. Of all 86 previously described DADA2 patients, immunoglobulin levels were reported for only 54 patients. Of those, 26 had hypogammaglobulinemia, and 10 had low levels of IgM. Of the latter, 3 also had low levels of IgA. Fifteen patients had normal immunoglobulin levels (1, (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Three children were described as having increased immunoglobulin levels (7, 19) , including 2 patients with a deletion encompassing CECR1 and IL17RA, who cannot be compared directly to the other patients with mutations in CECR1 only. Overall, immunologic assessment does not yet seem to be established as a routine evaluation of patients with DADA2. It was only reported in about half of the cases, even though B cell deficiency seems to be a more common trait of the disease than previously anticipated. Also, almost all of the patients who had an immunologic evaluation were pediatric patients, apart from our index patient who was 32 years old (5) and 3 others (1, 12, 16) . However, there are no immunologic data available on other adult DADA2 patients. We found that in our cohort of mainly adult patients, immunodeficiency was a common feature in all patients, clinically manifesting with recurrent infections in 82% (9 of 11). This strengthens our hypothesis that progressing inflammation may play an important role in establishing the immunodeficiency in DADA2.
Anti-TNF therapy can control inflammatory manifestations of DADA2 in many patients. We and others (Gattorno M: personal communication) found that anti-TNF treatment might also improve the immunologic features of the disease, possibly by reducing the inflammatory state of B cell development in DADA2. Also, suppression of the inflammatory process, often with lowering of CRP values, has so far prevented further vascular events in our adult patients, with the exception of a heart attack in a patient with known coronary heart disease. However, myalgias and abdominal pain still persist in selected patients.
Hematopoietic stem cell transplantation was discussed in 1 patient with severe neutropenia, who is currently dependent on GM-CSF treatment. Successful hematopoietic stem cell transplantation in DADA2 patients has been reported in 5 patients so far, including a boy with a combined immunodeficiency-like phenotype with 5 years of follow-up (11), a boy with a presumed diagnosis of atypical Diamond-Blackfan anemia with 13 years of follow-up (8), a child with pancytopenia and absence of B cells after treatment for acute myeloid leukemia, a child with corticosteroid-dependent autoimmune thrombocytopenia causing growth failure (15) , and a 20-year-old female with symptoms reminiscent of GATA-2 deficiency with 2 years of follow-up (16) . Even though various complications including nonengraftment (leading to a second hematopoietic stem cell transplantation), venoocclusive disease, and severe thrombocytopenia occurred in these patients, there was a 100% survival rate and a clear improvement in the clinical phenotype. However, the risk of hematopoietic stem cell transplantation is increased, especially in adults. In summary, conservative management, including anti-TNF treatment, immunoglobulin substitution, and antibiotic prophylaxis when required, has proven to be a safe and reliable option for our adolescent and adult patients.
To date, there is no consensus about the use of platelet inhibitors in DADA2. At the National Institutes of Health, platelet inhibition and anticoagulation therapy were discontinued in all DADA2 patients in order to prevent vascular events (20) . However, following the discontinuation of platelet inhibition in our adult DADA2 patients, one of them (patient 4, a 51-year-old woman) had a heart attack. Hence, close clinical followup and control of CRP values to detect increasing disease activity is crucial in monitoring these patients.
We did not see any evidence of a genotypephenotype correlation, and the position and type of the mutation had no influence on the amount of residual protein detected by Western blotting or on ADA2 enzymatic activity. The protein was uniformly absent, including in patient 3 who had isolated antibody deficiency and in 2 of our most severely affected patients, one with PAN (patient 4) and one with recurrent strokes (patient 1). There was even strong clinical variation between siblings with the same genotype and the same environmental background. This lack of genotypephenotype correlation was also noted by van Montfrans et al in a cohort of 9 patients carrying the same homozygous mutation R169Q (15) . Therefore, it remains difficult to draw conclusions on the prognosis of DADA2 in adulthood. In our cohort, conservative management provided good disease control in most patients. However, in severe cases, an early transplantation might prevent a fatal outcome. As one of our patients had his first stroke at only age 41, we strongly suggest that anti-TNF treatment should be considered even in patients without vascular manifestations, but with steadily and strongly elevated inflammation markers, indicating high disease activity, in order to prevent fatal vascular events.
Since the first description of mutations in CECR1 in 2014 (1,2), DADA2 has been primarily perceived as an autoinflammatory disease with vasculopathy. Since we found that DADA2 can also manifest solely with antibody deficiency (5), we screened a cohort of 181 patients with common variable immunodeficiency and antibody deficiency and found 9 additional DADA2 patients. There is a distinct immunodeficiency of the B cell compartment intrinsic to DADA2. This feature of the disease seems to worsen with increasing disease activity. However, this process seems to be stopped with efficient anti-TNF treatment. Conservative management has so far proven to be a good choice for our less severely affected adolescent and adult DADA2 patients. However, hematopoietic stem cell transplantation should be considered in patients with severe cytopenias and bone marrow failure. Our cohort of 11 DADA2 patients (4 adolescents and 7 adults) allows important insights on the prognosis and management of this disease in adulthood, serving as a guideline for adult medicine and allowing pediatricians to better estimate the prognosis of their patients upon a diagnosis of DADA2.
